The aim of this study was to compare the effect of pre-hospital treatment with prasugrel and clopidogrel on the TIMI flow in patients admitted in cath lab with acute STEMI in 2010. The primary efficacy endpoint was the superiority of TIMI flow in patients pretreated with prasugrel and reduction of use of Glycoprotein IIb/IIIa inhibitors in primary PCI. The key safety endpoint was tolerance of prasugrel and bleeding.
The primary efficacy endpoint occurred in 41% of patients receiving prasugrel and 33% of patients receiving clopidogrel (p=0.251).The subgroup (ST elevation within 6h ) had the maximal profit of TIMI FLOW with 44.1% in the prasugrel arm compared with 27.4% in the clopidogrel arm (p=0.088). No difference in the term of reduction of Glycoprotein IIB/IIIa inhibitors use in primary PCI (p=0.352) . The patients receiving prasugrel had a very good tolerance without elevation in rates of major bleeding.
In conclusion, there was no significant difference in term of TIMI Flow and use of Inhibitors of Glycoprotein IIb/IIIa in primary PCI between the prasugrel and clopidogrel groups. The patients presenting within 6h of ST segment elevation had a better TIMI flow if pretreated with prasugrel (P=0.088) with 16.67% gain in good TIMI flow in favor of prasugrel. More studies are needed.
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Single high sensitive troponin I test followed by coronary computed tomography for low risk patients admitted in chest pain unit
Edouard Cheneau [Orateur] Bruno Vahdat, Annamaria Molon, Dimitri Panagides Clinique Bouchard, Marseille, France Background: New troponin assays achieve early high sensitivity. A normal single high sensitive (HS) troponin at time of admission might rule out acute coronary syndrome.
Methods:
Patients with acute chest pain and low to intermediate likelihood of coronary artery disease were referred to a dedicated protocol in our chest pain unit. Patients with normal initial EKG and no noticeable alternative cause than ACS were evaluated by a single Troponin I test (Vitros I ES assay, threshold 0.012 ng/mL, 99 th percentile 0.034 ng/mL) at time of admission. All patients with normal HS troponin were referred to coronary computed tomography (CCT) angiography within 3 hours (General Electric 64-detectors Scan). Patients with suspected coronary obstruction by CCT were admitted and HS troponin aditionnally tested between 6 and 24 hours.
Results: Sixty eight patients (54+/-13 years) referred to our chest pain unit showed normal initial Troponin and EKG. Pre test-likelihood for coronary artery disease was 58%+/-24%. CCT was performed and coronary angiography reconstruction was evaluable in all patients. CCT showed significant obstruction (>50% stenosis) in 13 patients (19%). Invasive coronary angiography was performed and confirmed significant obstrution in 8 patients (12%). Multivessel disease was observed in 6 and TIMI flow was <3 in 3. Serial troponin sampling showed HS troponin elevation in only one patient.
Conclusions:
In low risk patients with acute chest pain, a normal single HS troponin sample does not rule out acute coronary syndrome. Increasing patient detection is more efficiently performed by Coronary CT at time of admission than HS troponin serial sampling. .87]). The incremental prognostic value of the RVPO information was confirmed by a decrease in the Akaike criterion, and increases in indices of calibration and discrimination when RVPO was added to the multivariate model. The threshold RVPO value for predicting adverse events was estimated at 35% (figure). Pts with RVPO >threshold at discharge had a significantly higher risk of death at 6m (p=0.01).
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Rapid non ST elevation myocardial infarction rule out with combination of copeptin and troponin in emergency department
Conclusion:
RPVO evaluated before hospital discharge in pts with intermediate-to high-risk PE is a powerful prognostic factor for outcome at 6m. RPVO t35% is associated with an increased risk of adverse events at 6m.
Paroxysmal supraventricular tachycardia-related adverse events
Béatrice Brembilla-Perrot [Orateur] (1), Jean-Marc Sellal (1), Pierre-Yves Zinzius (1), Jérôme Schwartz (1), Ibrahim Nossier (1), Soumaya Jarmouni (1), Daniel Beurrier (1), Anne Moulin-Zinsch (2), Pierre Louis (1), Olivier Selton (1), Thibaud Vaugrenard (1), Vladimir Manenti (1), Radou Moisei (1), Arnaud Terrier De La Chaise (1), Simona State (1), François Marçon (2) (1) CHU Brabois, Cardiologie, Vandoeuvre Les Nancy, France -(2) CHU Brabois, Cardiologie Pédiatrique, Vandoeuvre Les Nancy, France Paroxysmal supraventricular tachycardia (SVT) is considered as benign. The purpose of the study was to report the prevalence of SVT-related adverse events.
Methods: 1269 patients (pt), aged from 6 to 93 years with a normal ECG in sinus rhythm were recruited for SVT, confirmed by electrophysiological study. Pts with anterograde conduction through accessory pathway (AP) were excluded. SVT-related adverse events were collected.
Results: Adverse event occurs in 207 pts (16%) (group I, gr); 10 of them had a very serious event (gr I A): resuscitated ventricular fibrillation was provoked by SVT in 1 pt with coronary heart disease (HD), 1 pt with hypertrophic cardiomyopathy; 1 pt 55 years old, with respiratory failure, died after a prolonged SVT. Six pts presented resuscitated cardiac arrest after antiarrhythmic drugs used to stop SVT (sotalol, verapamil) . 197 pts presented with a poorly-tolerated SVT (gr I B), syncope (148), acute coronary syndrome (36), tachycardiomyopathy (6), stage IV of heart failure (5), inappropriate shock at ICD (1), collapsus after verapamil (1). Gr I was compared to pts without adverse events (gr II). Gr I was older than gr II (55±20 vs 49±18 years)(p<0.003). Male gender was more frequent in gr IB (53%) than in gr II (38%) (p<0.02). Underlying HD was more frequent in gr I (32%) than in gr II (6%) ( p<0.0000). The rate in tachycardia did not differ (183±41 bpm in gr I, 186±35 in gr II). SVT mechanism was similar: reentry in a concealed AP was noted in 19 % of gr I and II. Typical and atypical AV nodal reentrant tachycardias represented other causes. In gr II, 2 ablation-related deaths in old women and one sudden death 2 months after ablation were noted among 663 patients who had SVT ablation.
Conclusions: SVT-related adverse events occurred in 16% of patients. Advanced age, male gender and presence of HD were predisposing factors. However, life-threatening arrhythmias were rare and represented less than 1 %. Most of them were drug-related.
Levosimendan as a weaning strategy from inotropes
Didier Bresson [Orateur] F Sibellas, C Petitpe, O Bastien, Jj Lehot, V Cart-Regal, L Sebbag, E Bonnefoy USIC-Hôpital Cardiologique Louis Pradel, Bron, France Aims: Due to its prolonged declining clinical effect, levosimendan might help in weaning patients dependent on inotropes. We assessed the effect of a 24-hour infusion of levosimendan in a cohort of advanced heart failure patients dependent on dobutamine or milrinone.
Methods:
In this prospective observational study, 71 patients (pts), aged 58 [IQR: 44-63] years with advanced heart failure (28 ischaemic) and dependant on inotropes (define as failure of >2 consecutive trials in 7 days; dobutamine n=62, milrinone n=9) were included. They received a 24-hour intravenous infusion of levosimendan (0.1 μg/kg/min) in the ICU. 4 of them had an intra-aortic balloon pump. Success was defined as "alive and free from inotrope" at the end of ICU stay.
Results:
The median time from hospital admission to beginning of levosimendan infusion was 16 [IQR:5.5-29.2] days. Fifty five pts (76.1%) were alive and free of dobutamine or milrinone 48H after initiation of levosimendan. Four patients failed to receive the full levosimendan amount and 9 patients (16%) had to receive norepinephrine because of hypotension. Atrial fibrillation occurred in 9 pts (12.7%). Median time to stop dobutamine or milrinone was 18 [IQR:4.5-24] hours. Reinitiation of inotropes was needed in 3 pts.
